Scanner logic
Why this stock appeared
GRANULES appeared because the stored NiftyLens scanner found a market-behaviour observation on 2026-07-27. The scanner review is based on multi-year technical price history, recent daily behaviour, participation, liquidity, relative movement, and post-observation tracking fields before public context is attached. This page labels it as a neutral watch observation, meaning it is kept for educational review without presenting the scanner output as a trading instruction.
After the scanner observation, NiftyLens checks public news and corporate-event context to help readers study what else was visible around the same market day. That context is an explanation layer, not a trading instruction.
Public news and event check
Granules India has received notable regulatory approval by securing sole first-to-file status for its generic version of the narcolepsy drug Lumryz (sodium oxybate) in the US market, a move that strengthens its complex generics portfolio and was followed by a reported stock surge touching a 52-week high [6][8]. Additionally, the company has announced a Board Meeting on July 21, 2026, to approve Unaudited Financial R...